Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?

Documenti analoghi

• Two years with GIOIA ‘Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes’: A prospective, multicentre, quasi‐experimental study on sodium‐glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors in diabetes clinical practice
  di: Miriam Longo, et al.
  Pubblicazione: (2024)
• Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial
  di: Paola Caruso, et al.
  Pubblicazione: (2025)
• Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts
  di: Paola Caruso, et al.
  Pubblicazione: (2025)
• Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps
  di: Robert L. Dubin, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials
  di: Giovanni Antonio Silverii, et al.
  Pubblicazione: (2024)